Buchumschlag

Valuation and returns of drug development companies: lessons for bioentrepreneurs and investors

This study evaluates the association of Biopharma company valuation with the lead drug’s development stage, orphan status, number of indications, and disease area. We also estimated annual returns Bioentrepreneurs and investors can expect from founding and investing in drug development ventures.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Michaeli, Daniel (VerfasserIn) , Yagmur, Hasan Basri (VerfasserIn) , Achmadeev, Timur (VerfasserIn) , Michaeli, Christoph T. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 11. January 2022
In: Therapeutic innovation & regulatory science
Year: 2022, Jahrgang: 56, Heft: 2, Pages: 313-322
ISSN:2168-4804
DOI:10.1007/s43441-021-00364-y
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s43441-021-00364-y
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s43441-021-00364-y
Volltext
Verfasserangaben:Daniel Tobias Michaeli, Hasan Basri Yagmur, Timur Achmadeev, Thomas Michaeli
Beschreibung
Zusammenfassung:This study evaluates the association of Biopharma company valuation with the lead drug’s development stage, orphan status, number of indications, and disease area. We also estimated annual returns Bioentrepreneurs and investors can expect from founding and investing in drug development ventures.
Beschreibung:Gesehen am 29.04.2024
Beschreibung:Online Resource
ISSN:2168-4804
DOI:10.1007/s43441-021-00364-y

Ähnliche Einträge